For years, patients with multiple sclerosis have had to rely on injectable medications. But several new oral medications are emerging, and one drug has already been approved by the FDA. Why has it taken so long to develop oral formulations? Dr. Jeffrey Cohen, director of the Millen Experimental Therapeutics program at the Cleveland Clinic and professor of medicine at the Cleveland Clinic Lerner College of Medicine, joins host Dr. Anthony Alessi to discuss how these new drugs work, the side effects, and which patients can most benefit from new oral therapy.
Produced in cooperation with: